|
Market Closed -
NYSE
21:00:00 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 1.080 USD | -1.82% |
|
-6.90% | -35.33% |
| 08-07 | Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Lineage Cell Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 278.2 | - | - |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -31.26% | - | - |
| Enterprise Value (EV) | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 278.2 | 278.2 | 278.2 |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -31.26% | 0% | 0% |
| P/E | -9.42x | -7.8x | -9.08x | -5.58x | -5.96x | -16.1x | -10.4x | 135x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.5x | 0.2x | -0x | 0.2x | -0.2x | -1x |
| Capitalization / Revenue | 95.1x | 13.5x | 21.3x | 11.7x | 27.8x | 18.3x | 16.5x | 4.66x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 18.3x | 16.5x | 4.66x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -8.27x | -9.46x | -9.07x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -8.77x | -10.1x | 42.6x |
| EV / FCF | - | 0x | -0x | -0x | -0x | -23.2x | -31.3x | 76.2x |
| FCF Yield | - | 0.32% | -15.3% | -21.4% | -4.8% | -4.31% | -3.2% | 1.31% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.26 | -0.15 | -0.12 | -0.09 | -0.28 | -0.0671 | -0.1043 | 0.008 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.341 | 14.7 | 8.945 | 9.499 | 14.56 | 15.19 | 16.83 | 59.72 |
| EBITDA 1 | -48.34 | -21.79 | -24.04 | -20.87 | -35.92 | -33.64 | -29.41 | -30.66 |
| EBIT 1 | -49.21 | -22.52 | -24.73 | -21.48 | -36.62 | -31.71 | -27.47 | 6.528 |
| Net income 1 | -43.02 | -26.27 | -21.49 | -18.61 | -63.53 | -22.64 | -34.44 | 6.022 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 2.450 | 1.170 | 1.090 | 0.502 | 1.670 | 1.080 | 1.080 | 1.080 |
| Nbr of stocks (in thousands) | 168,558 | 169,976 | 174,987 | 220,416 | 242,328 | 252,907 | - | - |
| Announcement Date | 10/03/22 | 09/03/23 | 07/03/24 | 10/03/25 | 05/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -16.38x | - | - | - | 278M | |
| 33.99x | 6.09x | 18.25x | 0.94% | 50.35B | |
| -21.55x | 255.32x | -23.29x | -.--% | 45.2B | |
| 34.98x | 3.36x | 14.51x | -.--% | 44.71B | |
| 47.51x | 5.49x | 30.13x | -.--% | 41.24B | |
| 28.36x | 8.58x | 21.72x | 0.41% | 33.08B | |
| 33.74x | 5.53x | 25.11x | -.--% | 16.56B | |
| 24.49x | 2.12x | 9.19x | 1.1% | 14.82B | |
| 78.47x | 4.12x | 15.98x | -.--% | 14B | |
| Average | 27.07x | 36.33x | 13.95x | 0.31% | 28.91B | |
| Weighted average by Cap. | 27.72x | 48.81x | 12.51x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LCTX Stock
- Valuation Lineage Cell Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
